Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nanopore Technologies Regulatory News (ONT)

Share Price Information for Oxford Nanopore Technologies (ONT)

Share Price is delayed by 15 minutes
Get Live Data
124.10    -1.80 (-1.43%)
Bid:
123.70
Ask:
124.20
Spread: 0.50 (0.404%)
Market Cap: £1.21b
ONT Live PriceLast checked at - London Stock Exchange

Intraday Oxford Nanopore Technologies Share Chart

Changes to the senior leadership team

11 Nov 2024 07:00

RNS Number : 6493L
Oxford Nanopore Technologies plc
11 November 2024
 
 

11 November 2024

Oxford Nanopore Technologies plc

("Oxford Nanopore" or the "Company")

Oxford Nanopore announces changes to the senior leadership team

Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore-based molecular sensing technology, today announces that Rosemary Sinclair Dokos has been appointed as Chief Product and Marketing Officer and Dr Lakmal Jayasinghe has been appointed as Chief Scientific Officer, effective immediately. Rosemary and Lakmal, who will report to Chief Executive Officer Dr Gordon Sanghera, succeed Clive Brown, Chief Officer of Technology, Innovation, and Products, who has stepped down to pursue new projects. Clive will be available to the business on an advisory basis to support an effective transition.

Rosemary has more than 18 years' experience in innovation, including product management and commercial functions. She joined Oxford Nanopore in 2014 and has been a pivotal force in driving the Company's product strategy and execution, overseeing the development of Oxford Nanopore's platform technologies, including the recent PromethION 2 and GridION Q-Line launches. In her new role, Rosemary will continue leading the development of products that include new multiomic, clinical, biopharma and industrial applications, in addition to platform technology innovations and marketing.

Lakmal is a highly respected, world-leading nanopore and protein sensing scientist and scientific leader, with more than 18 years' experience. He joined Oxford Nanopore in 2007 and has been responsible for all biological research and development projects at Oxford Nanopore. Lakmal will continue to lead efforts to integrate new multiomic capabilities, including genomics, transcriptomics, proteomics, and metabolomics, into the Company's platform.

Dr Gordon Sanghera, Chief Executive Officer of Oxford Nanopore, commented:

"Rosemary and Lakmal have played an integral role in the research, development and execution of our technology vision for many years. They bring extensive skills in innovation and product development, and the leadership of highly skilled technical teams. These span the most cutting-edge innovation to the deployment of mature products destined for regulated markets - critical to creating stakeholder value. Their knowledge, perspective and vision will advance our innovation leadership and fuel the continuation of our growth journey.

 

"I would like to thank Clive for his profound contributions to the development of the technology and the growth of the business over the past 16 years. He established the Company's distinct vision of distributed, accessible sequencing and fostered a culture of cutting-edge innovation and relentless pursuit of pushing technological boundaries, which has shaped Oxford Nanopore into the innovative force it is today. We continue to deliver against this vision and will carry forward his drive to deploy big ideas and solve big problems."

 

Clive Brown, former Chief Officer of Technology, Innovation, and Products at Oxford Nanopore, commented:

"It has been a privilege to work alongside Gordon, Spike and the leadership team and I am proud of all that we have achieved over the last 16 years. Given our progress, I am now pursuing my next professional challenge. Rosemary's focus on transformative product experiences and Lakmal's pioneering work in multiomics put the Company in a strong position for the next phase of its development. I would particularly like to thank the user community, who continue to work so hard to help us improve and innovate the technology to enable them to perform breakthrough science. I remain a dedicated shareholder and look forward to seeing the Company continue to go from strength to strength."

 

-ENDS-

For further information, please contact:

Oxford Nanopore Technologies plc

Investors: ir@nanoporetech.com

Media: media@nanoporetech.com

 

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

   

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture. For more information please visit: www.nanoporetech.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPGWWGUPCPPU
Date   Source Headline
4th Jun 20262:30 pmRNSResult of AGM
1st Jun 20264:00 pmRNSIssue of Equity and Total Voting Rights
21st May 20267:01 amRNSLondon Calling Technology Update
21st May 20267:00 amRNSOxford Nanopore strengthens executive team
13th May 20263:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th May 20267:00 amRNSDirector/PDMR Shareholding
1st May 20263:00 pmRNSIssue of Equity and Total Voting Rights
1st May 20267:00 amRNSPublication of Annual Report and Notice of AGM
15th Apr 20265:30 pmRNSDirector/PDMR Shareholding - LTIP and DBP awards
14th Apr 20264:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
13th Apr 20263:00 pmRNSDirector/PDMR Shareholding - LTIP and DBP awards
1st Apr 20263:00 pmRNSIssue of Equity and Total Voting Rights
26th Mar 20263:00 pmRNSBlock Admission Application
4th Mar 20267:00 amRNS-RUpcoming Investor Events and Conferences
3rd Mar 20264:00 pmRNSGrant of LTIP awards; Director/PDMR Notification
3rd Mar 20267:00 amRNSDirector/PDMR Shareholding
2nd Mar 20264:00 pmRNSIssue of Equity and Total Voting Rights
2nd Mar 20267:00 amRNSAnnual results for the year ended 31 December 2025
27th Feb 20263:00 pmRNSUpdate on legal action against MGI Australia
27th Feb 20261:30 pmRNSDirector Declaration - John O'Higgins
12th Feb 20264:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
2nd Feb 20263:00 pmRNSIssue of Equity and Total Voting Rights
14th Jan 20264:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Jan 20267:00 amRNSFull Year Trading Update and Notice of Results
7th Jan 20267:00 amRNS-RUpcoming Investor Events and Conferences
2nd Jan 20263:00 pmRNSIssue of Equity and Total Voting Rights
12th Dec 20253:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
8th Dec 20259:00 amRNSAGM Post-Meeting Shareholder Engagement Update
8th Dec 20257:00 amRNSAppointment of Francis Van Parys as CEO
1st Dec 20254:00 pmRNSIssue of Equity and Total Voting Rights
27th Nov 20257:00 amRNS-RUpcoming investor conferences
12th Nov 20254:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
7th Nov 20259:00 amRNSONT postpones investor event; reaffirms guidance
3rd Nov 20253:00 pmRNSIssue of Equity and Total Voting Rights
16th Oct 20257:00 amRNS-RUpcoming Investor Conferences and Events
14th Oct 20254:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
6th Oct 20255:30 pmRNSBlock listing Interim Review
1st Oct 20254:00 pmRNSIssue of Equity and Total Voting Rights
12th Sep 20254:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
2nd Sep 20257:00 amRNSInterim results for the 6 months ended 30 June 25
1st Sep 20255:00 pmRNSIssue of Equity and Total Voting Rights
13th Aug 20254:00 pmRNSShare Incentive Plan - Director/PDMR Notification
11th Aug 20257:00 amRNSChief Executive Officer Succession
8th Aug 20257:00 amRNSResult of Audit Tender
6th Aug 20257:00 amRNSCommencement of legal action against MGI Australia
1st Aug 20254:30 pmRNSIssue of Equity and Total Voting Rights
29th Jul 20257:00 amRNSHolding(s) in Company
21st Jul 20257:00 amRNSHalf Year Trading Update and Notice of Results
14th Jul 20256:00 pmRNSShare Incentive Plan - Director/PDMR Notification
4th Jul 20254:30 pmRNS-RPublication of 2024 Sustainability Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.